What company owns Genzyme?

Sanofi
Genzyme/Parent organizations
PARIS (Reuters) – French drugmaker Sanofi-Aventis SA clinched its long-sought deal for Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group’s drugs.

What happened to Genzyme?

Genzyme was acquired by Sanofi for $20Bn back in 2011, which is one of the biggest Biotech deals in history. For many people, Genzyme’s acquisition was considered as an ‘anomaly’ within the industry.

Is Genzyme part of Sanofi?

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, neurology, immunology, and oncology.

Why did Sanofi buy Genzyme?

The companies agreed in February on a deal worth about $20.1 billion. The acquisition gives Sanofi access to Genzyme’s business in treating rare diseases and is expected to help the company combat sales erosion from drugs facing cheap generic competition. Genzyme shares closed down 0.1 percent at $76.25 on Nasdaq.

Where is Sanofi Genzyme plant in Boston MA?

Now the firm has confirmed it has acquired Sanofi’s Allston facility in Boston, Massachusetts (across the Charles River from Cambridge) for an undisclosed fee. Sanofi’s facility in Allston, Boston, MA.

Where is the Genzyme building at Harvard Business School?

The company, founded in November, has raised more than $800 million in capital and agreed to assume the lease on the building, a former Genzyme manufacturing plant built in 1991. The facility sits on Harvard-owned land across from Harvard Business School’s One Western Avenue graduate residence.

Where is the Sanofi building in Allston located?

National Resilience, a new life sciences startup, will take over the lease on the Sanofi Building, the former Genzyme plant on Soldiers Field Road in Allston. ‘I’ve never done work that I was not interested in.

When did the Allston Massachusetts plant shut down?

At the time, the Allston plant was under regulatory scrutiny. The plant temporarily shut down production in 2009 due to viral contamination and in March the following year the firm was issued with a US FDA consent decree.